Starpharma Holdings Limited (ASX:SPL): Dendrimer Oncology Pipeline Advances Alongside New Funding

Aditi Sarkar

30 October 2026 08:16 PM AEDT

Starpharma Holdings Limited (ASX:SPL): Dendrimer Oncology Pipeline Advances Alongside New Funding

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 revenue reached $12.0 million, reflecting licensing income and other activities.
September-quarter cash was $34.4 million, with a subsequent research tax incentive received.
A Clinical Trial Application was submitted for the DEP HER2-Lu first-in-human study.
Starpharma acquired majority ownership of a targeted oncology development program.

Starpharma Holdings Limited develops dendrimer-based biotechnology with an emphasis on targeted cancer therapies and drug-delivery applicationsStarpharma Holdings Limited (ASX:SPL) has been progressing its DEP oncology pipeline while reporting changes in funding, partnership activity and research priorities during FY26 and the September quarter.

Research programs and clinical preparations

Starpharma Holdings Limited (ASX:SPL) reported that a Clinical Trial Application had been submitted in Europe for a first-in-human Phase 1 study of DEP HER2-Lu. The program is intended to investigate a targeted radiopharmaceutical in patients with HER2-expressing cancers. Submitting an application represents a regulatory step, not trial approval, and patient dosing depends on the applicable review and operational preparations.

During the September 2026 quarter, the company completed manufacture of non-radiolabelled clinical material and worked on the radiolabelling process, analytical procedures and quality-control activities. The initial clinical stage is designed to assess safety, tolerability, distribution in the body and radiation dosimetry. These measures relate to how the proposed treatment behaves and are separate from establishing therapeutic effectiveness.

Starpharma Holdings Limited (ASX:SPL) also reported filing a patent application relating to the use of its DEP technology in radioligand therapy. Preclinical work was described across several oncology targets. Laboratory and animal findings remain distinct from evidence generated through clinical testing, so the proposed applications remain at different stages of development.

Financial position and strategic investments

In its FY26 results, Starpharma Holdings Limited (ASX:SPL) reported revenue of $12.0 million, an increase of 145% year on year. An $8.3 million upfront payment under a licensing arrangement was the principal contributor. The company reported a FY26 loss of $7.5 million, an improvement of 25% year on year, and cash of $11.0 million at 30 June 2026.

A fully underwritten entitlement offer subsequently generated approximately $30 million in net proceeds. At 30 September 2026, cash stood at $34.4 million. A further $3.5 million research and development tax incentive was received on 22 October 2026, leading to a pro forma cash figure of $37.9 million as disclosed in the quarterly report. These figures refer to different dates and should not be treated as interchangeable balances.

On 20 October 2026, Starpharma Holdings Limited (ASX:SPL) disclosed that its ownership of Petalion Therapeutics had increased from 22.5% to 66%. The company agreed to contribute up to AUD $5.0 million, comprising AUD $3.0 million of cash and up to AUD $2.0 million in research services. The arrangement expands the company's involvement in a fibroblast activation protein-targeted oncology program and introduces further research commitments.

Development dependencies and operational priorities

The company continues to rely on research progress, clinical authorisations and commercial counterparties to advance its development activities. The planned first-in-human study cannot establish an outcome before patients are enrolled and evaluated. Starpharma Holdings Limited (ASX:SPL) has separately identified licensing arrangements and product-related income as sources of commercial activity, although receipts can vary according to contract terms and project stages.

The Petalion investment also adds a distinct research pathway at an earlier stage than the proposed HER2-Lu clinical study. Candidate selection, subsequent testing and any partnering decisions are not equivalent to an approved medical product. The cash position provides financial resources for these activities, while future expenditure remains linked to clinical development and the broader research program.

Key Insights

Starpharma Holdings Limited (ASX:SPL) entered the final quarter of calendar 2026 with a larger cash balance, a submitted clinical application and control of an additional oncology program. FY26 income was materially affected by an upfront licence payment, while clinical and research milestones remain subject to review and execution.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.